A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) (ROCKET-VOYAGER)

June 25, 2026 updated by: Amgen

A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

The primary objectives of this study are to:

  • estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24
  • estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 24

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
221

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Canada
    • Alberta
      • Edmonton, Alberta, Canada, T6W 4V4
        • Skin Physicians Dermatology
    • British Columbia
      • Kelowna, British Columbia, Canada, V1W 4V5
        • Interior Dermatology Centre
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada, A1E 1V4
        • Skincare Studio
      • St. John's, Newfoundland and Labrador, Canada, A1A 4Y3
        • Karma Clinical Trials
    • Ontario
      • Etobicoke, Ontario, Canada, M8X 1Y9
        • Kingsway Clinical Research
      • Guelph, Ontario, Canada, N1L 0B7
        • Guelph Dermatology Research
      • Richmond Hill, Ontario, Canada, L4C 9M7
        • York Dermatology Centre
      • Toronto, Ontario, Canada, M5G 1E2
        • Evidence Based Medical Educator Inc
      • Toronto, Ontario, Canada, M5M 3Z8
        • DermAtelier Clinical Research Incorporated
      • Toronto, Ontario, Canada, M4E 1R7
        • FACET Dermatology
    • Quebec
      • Montreal, Quebec, Canada, H1Y 3L1
        • Clinique de Dermatologie Rosemont
      • Québec, Quebec, Canada, G1W 4R4
        • Centre de Recherche Saint-Louis
      • Verdun, Quebec, Canada, H4G 3E7
        • SIMa Recherche
  • United States
    • Arizona
      • Scottsdale, Arizona, United States, 85260
        • Center for Dermatology and Plastic Surgery
      • Scottsdale, Arizona, United States, 85260
        • Scottsdale Clinical Trials
      • Scottsdale, Arizona, United States, 85255
        • Affiliated Dermatology
      • Tempe, Arizona, United States, 85283
        • Medical Advancement Centers of Arizona
    • Arkansas
      • Little Rock, Arkansas, United States, 72205
        • Little Rock Allergy and Asthma Clinical Research Center
    • California
      • Bakersfield, California, United States, 93301
        • Kern Research Inc
      • Canoga Park, California, United States, 91303
        • Hope Clinical Research LLC
      • Chino, California, United States, 91710
        • Doc1 Healthcare Systems
      • Inglewood, California, United States, 90301
        • 310 Clinical Research
      • Lancaster, California, United States, 93534
        • Chemidox Clinical Trials Incorporated
      • Long Beach, California, United States, 90805
        • Long Beach Research Institute
      • Los Angeles, California, United States, 90024
        • University of California Los Angeles
      • Los Angeles, California, United States, 90056
        • Wallace Medical Group Inc
      • Los Angeles, California, United States, 90067
        • West Los Angeles Clinical Trials
      • Northridge, California, United States, 91325
        • Northridge Clinical Trials
      • Pasadena, California, United States, 91105
        • Havana Research Institute Inc
      • Rolling Hills Estates, California, United States, 90274
        • Peninsula Research Associates
      • Sacramento, California, United States, 95815
        • Integrative Skin Science and Research
      • San Diego, California, United States, 92120
        • Wake Research Medical Center for Clinical Research
      • Sherman Oaks, California, United States, 91403
        • Cura Clinical Research
      • Tustin, California, United States, 92780
        • Wolverine Clinical Trials
    • Florida
      • Coral Gables, Florida, United States, 33134
        • Alliance for Multispecialty Research
      • Coral Springs, Florida, United States, 33071
        • Life Clinical Trials
      • Destin, Florida, United States, 32541
        • AllerVie Clinical Research- Destin
      • Doral, Florida, United States, 33172
        • Saint Jude Clinical Research
      • Doral, Florida, United States, 33122
        • D and H Doral Research Centers
      • Hialeah, Florida, United States, 33012
        • Direct Helpers Research Center
      • Homestead, Florida, United States, 33033
        • Nexus Clinical Research
      • Miami, Florida, United States, 33155
        • D and H National Research Centers
      • Miami, Florida, United States, 33155
        • Gold Coast Health Research Center
      • Miami, Florida, United States, 33176
        • Anchor Medical Research
      • Miami Gardens, Florida, United States, 33014
        • Meridian International Research
      • Ocala, Florida, United States, 34471
        • AllerVie Clinical Research- Ocala
      • Tamarac, Florida, United States, 33321
        • D and H Tamarac Research Centers
    • Georgia
      • Alpharetta, Georgia, United States, 30022
        • Hamilton Research, LLC
      • Atlanta, Georgia, United States, 30315
        • Divine Dermatology and Aesthetics
      • Atlanta, Georgia, United States, 30342
        • MetroDerm / Atlanta Center for Clinical Research, LLC
      • Fayetteville, Georgia, United States, 30214
        • First Georgia Physicians Group
      • Macon, Georgia, United States, 31217
        • Dermatologic Surgery Specialists
      • Thomasville, Georgia, United States, 31792
        • McIntosh Clinic PC
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Indiana University School of Medicine
      • New Albany, Indiana, United States, 47150
        • Southern Indiana Clinical Trials
    • Kansas
      • Leawood, Kansas, United States, 66211
        • Dermatology and Skin Cancer Center Leawood
    • Maryland
      • Largo, Maryland, United States, 20774
        • Visage Dermatology and Aesthetic Center
    • Massachusetts
      • Methuen, Massachusetts, United States, 01844
        • ActivMed Practices and Research, LLC
    • Michigan
      • Auburn Hills, Michigan, United States, 48326
        • Oakland Hills Dermatology
      • Caledonia, Michigan, United States, 49316
        • The Derm Institute of West Michigan
    • Nevada
      • Las Vegas, Nevada, United States, 89109
        • Excel Clinical Research
      • North Las Vegas, Nevada, United States, 89030
        • Las Vegas Clinical Trials
      • Reno, Nevada, United States, 89509
        • Skin Cancer and Dermatology Institute
    • New Mexico
      • Albuquerque, New Mexico, United States, 87102
        • University of New Mexico Cancer Center
    • New York
      • Kew Gardens, New York, United States, 11415
        • Forest Hills Dermatology Group
      • New York, New York, United States, 10016
        • Pioneer Clinical Research New York
      • Rochester, New York, United States, 14609
        • Rochester Clinical Research Inc
    • North Carolina
      • Hickory, North Carolina, United States, 28602
        • Hickory Dermatology Research Center
      • Matthews, North Carolina, United States, 28105
        • Tryon Medical Partners
      • Winston-Salem, North Carolina, United States, 27103
        • The Skin Surgery Center
    • Ohio
      • Mayfield Heights, Ohio, United States, 44124
        • Apex Clinical Research Center LLC
      • Springfield, Ohio, United States, 45505
        • Dermatologist of Central States Clinical Research - Springfield
    • Oklahoma
      • Chickasha, Oklahoma, United States, 73018
        • Epic Medical Research - Oklahoma
      • Oklahoma City, Oklahoma, United States, 73118
        • Unity Clinical Research
      • Tulsa, Oklahoma, United States, 74132
        • Dermatology Research Center of Oklahoma, PLLC
    • Oregon
      • Medford, Oregon, United States, 97504
        • Velocity Clinical Research Inc
      • Portland, Oregon, United States, 97210
        • Oregon Dermatology and Research Center
    • South Carolina
      • Charleston, South Carolina, United States, 29425
        • Medical University of South Carolina
    • Tennessee
      • Hermitage, Tennessee, United States, 37076
        • Cumberland Skin Center
    • Texas
      • Houston, Texas, United States, 77037
        • MedCare Pharma - Houston
      • Mesquite, Texas, United States, 75149
        • Sms Clinical Research Limited Liability Company
      • Southlake, Texas, United States, 76092
        • Stryde Research - Epiphany Dermatology
      • Webster, Texas, United States, 77598
        • Tranquil Clinical Research
    • Utah
      • Bountiful, Utah, United States, 84010
        • Cope Family Medicine
      • Murray, Utah, United States, 84107
        • Tanner Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 18 years to 54 years with a diagnosis of AD according to the American Academy of Dermatology (AAD) Consensus Criteria (2014) present for at least 12 months
  • History of inadequate response to topical corticosteroids (TCS) of medium, high, or higher potency (with or without topical calcineurin inhibitors)
  • Subjects with previous systemic treatment for AD are also considered as inadequate responders to topical treatments and are potentially eligible to be included in the study after appropriate washout.
  • Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score ≥ 3

Exclusion Criteria:

  • Treatment with a biologic product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1

  • Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:

    • Systemic corticosteroids
    • Systemic immunosuppressants
    • Phototherapy
    • Janus kinase inhibitors

  • Treatment with any of the following medications or therapies within 1 week, prior to Day 1:

    • TCS of any potency
    • Topical calcineurin inhibitors (TCI)
    • Topical Phosphodiesterase-4 inhibitors (PDE4)
    • Other topical immunosuppressive agents
    • Combination topical agents containing a corticosteroid or calcineurin inhibiting component, PDE4 inhibitors, or other topical immunosuppressive agents
  • Treatment with live virus including live attenuated vaccination 12 weeks prior to day 1 pre-randomization.
  • Treatment with any meningococcal vaccine within 1 year prior to screening, or treatment with any tetanus-, diphtheria-, or pertussis containing vaccine within 5 years prior to screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Rocatinlimab
Rocatinlimab every 4 weeks (Q4W) for 24 weeks with a loading dose at Week 2.
Drug: Rocatinlimab
Subcutaneous (SC) injection
Other Names:
  • AMG 451
  • KHK4083
Placebo Comparator: Placebo
Placebo every 4 weeks (Q4W) for 24 weeks with a loading dose at Week 2.
Drug: Placebo
SC injection

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percentage of Participants With a Positive Anti-tetanus Response at Week 24
Time Frame: Week 20 to Week 24
Participants received 1 dose of a tetanus vaccine at Week 20. The antibody response to the tetanus vaccine was assessed by measuring serum anti-tetanus immunoglobulin G (IgG) by an immunoassay.
Week 20 to Week 24
Percentage of Participants With a Positive Anti-meningococcal Response at Week 24
Time Frame: Week 20 to Week 24
Participants received 1 dose of a meningococcal vaccine at Week 20. The antibody response to the meningococcal vaccine was assessed by measuring serum anti-meningococcal IgG by an immunoassay.
Week 20 to Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Amgen

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: MD, Amgen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 7, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 26, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 14, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 2, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 2, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 12, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 23, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 25, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 20210158

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

IPD Sharing Time Frame

Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

IPD Sharing Access Criteria

Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings